[P3-1] Surgical Treatment: Controversies and Challenges in Surgical Treatment for Early Breast Cancer

[P3-2] Adjuvant Clinical Trials Overview; Optimizing Chemo/Endocrine Therapy to Individualized Patients

[P3-3] Breaking News about On-going Clinical Trials

[S4-1] Neoadjuvant Chemotherapy for Operable Breast Cancer

[S4-2] Adjuvant Trastuzumab; Timing, Duration, Management of Toxicity

[S4-3] Update on Systemic Therapy for Women with Metastatic Disease

[S4-4] Emerging Targeted Agents for Breast Cancer Treatment

[S5-1] Micrometastasis in SLN; Clinical and Pathological Significance

[S5-2] Biological Evaluation and Strategy for Triple Negative Breast Cancer

[S5-3] HER-2 Standardization Program in Korea

[S5-4] Third Generation Adjuvant Chemotherapy - Increasing Efficacy, Minimising Toxicity

[S6-1] Mammography and Ultrasound Findings of Breast Cancer

[S6-2] Roles of MRI in Breast Cancer Treatment and Research

[S6-3] Roles of PET/PET‐CT in Breast Cancer Treatment and Research

[S6-4] Monitoring of Cell Therapy with MR Imaging

[P4-1] How and Why Patient-oncologist Communication Matters in Breast Cancer

[P4-2] Needs of Korean Women with Breast Cancer and Their Quality of Life

[P4-3] Emotional Well-being for People with Breast Cancer

[S7-1] SLN Biopsy Technique; Is There the Best One?

[S7-2] The Current Status of SLN Biopsy of Breast Cancer in China

[S7-3] Safety Margins for Lumpectomy; How Close Is Too Close?

[S7-4] Breast Conserving Treatment in Japan: Long-term Follow-up Results and Issues to Be Addressed

[S8-1] Measurement of HRQOL in Korean Breast Cancer Patients

[S8-2] The Meaning of Prayer in Patient with Breast Cancer

[S8-3] Subgroups of Women with Breast Cancer with Different Symptom Experiences and Outcomes: A Cluster Analysis

[S8-4] Coping of Chinese Women with Breast Cancer

[S9-1] Multicenter Clinical Trials in Korea

[S9-2] Multicenter Clinical Trials in Japan

[S9-3] On-going Clinical in NSABP

[S9-4] Current and Future Direction for Clinical Trials in Breast Cancer